Page last updated: 2024-12-05

2-toluidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-toluidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

o-toluidine : An aminotoluene in which the amino substituent is ortho to the methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7242
CHEMBL ID1381
CHEBI ID66892
SCHEMBL ID15789
MeSH IDM0081065

Synonyms (115)

Synonym
2-aminotoluene (o-toluidine)
BIDD:ER0679
wln: zr b1
benzenamine, 2-methyl-
2-amino-1-methylbenzene
nsc-15348
2-methyl-1-aminobenzene
o-toluidyna
o-tolylamine
2-toluidine
2-aminotoluene
o-methylaniline
o-toluidin
1-amino-2-methylbenzene
1-methyl-2-aminobenzene
95-53-4
o-toluidine
2-methylbenzenamine
o-methylbenzenamine
nsc15348
o-aminotoluene
aniline, 2-methyl-
2-methylaniline
inchi=1/c7h9n/c1-6-4-2-3-5-7(6)8/h2-5h,8h2,1h
ortho-toluidine
NCGC00091368-01
hsdb 2042
c.i. 37077
2-methylbenzamine
rcra waste no. u328
rcra waste number u328
ai3-24383
nsc 15348
ccris 597
o-toluidin [czech]
o-toluidyna [polish]
einecs 202-429-0
o-toluidine, 98%
o-toluidine, >=99%
C90102
smr001370921
MLS002415766
CHEMBL1381
chebi:66892 ,
o-toluidine(1%)
T0299
AKOS000119109
NCGC00091368-04
NCGC00091368-03
NCGC00091368-02
HMS3039B11
NCGC00253986-01
tox21_201256
dtxcid206164
NCGC00258808-01
tox21_300179
cas-95-53-4
dtxsid1026164 ,
STL163331
o-tolyl-amine
FT-0675282
unii-b635mz0zlu
ortho toluidine
ec 202-429-0
b635mz0zlu ,
o-toluidine, liquid or solid [un1708] [poison]
o-toluidine, liquid or solid
2-methylphenylamine
benzenamine, methyl-
121536-13-8
2-toluidine-d7
68408-22-0
prilocaine impurity b [ep impurity]
ortho-toluidine [iarc]
prilocaine hydrochloride impurity b [ep impurity]
2-tolylamine
2-aminotoluene [hsdb]
o-toluidine [mi]
BP-21341
SCHEMBL15789
2-methyl aniline
2 -methylaniline
2-methyl-aniline
ortho-tolylamine
2-amino toluene
o-toluide
AM87484
51v ,
mfcd00007730
F2190-0418
o-toluidine, purum p.a., >=99.5% (gc)
o-toluidine, saj special grade, >=99.0%
o-toluidine, analytical standard
o-toluidine, liquid
o-toluidine, p.a., 99.5%
Z57127943
2-methylbenzenamine (o-toluidine)
o-toluidine 100 microg/ml in cyclohexane
o-toluidine 10 microg/ml in cyclohexane
o-toluidine 500 microg/ml in methanol
2-methyl-benzenamine
o-toluidin (czech)
o-toluidine (acd/name 4.0)
2-methylphenylamine (acd/name 4.0)
o-toluidyna (polish)
BCP17522
Q311695
STR00213
2-(methyl)aniline
o-toluidine-d3 (methyl-d3)
EN300-33459
ci 37077
prilocaine impurity b (ep impurity)
ortho-toluidine (iarc)
toluidine (ortho)

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The proposed method was based on two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry (SPE/LC-MS/MS)."( Rapid determination of six carcinogenic primary aromatic amines in mainstream cigarette smoke by two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry.
Bie, Z; Chen, Y; Ji, L; Lu, W; Ren, H; Zhu, Y, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" We studied bioavailability and changes in methemoglobin levels following topical penile exposure to 1 g of EMLA cream for 1 hour in piglets."( Penile absorption of EMLA cream in piglets: implications for use of EMLA in neonatal circumcision.
Gazarian, M; Kent, G; Klein, J; Koren, G; Taddio, A, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminotolueneAny member of the class of toluenes carrying one or more amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency44.66840.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.79520.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency4.42110.001530.607315,848.9004AID1224841; AID1224842; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.45100.000229.305416,493.5996AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588537
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.81830.001628.015177.1139AID1224843; AID1224895
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (168)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (23.81)18.7374
1990's32 (19.05)18.2507
2000's43 (25.60)29.6817
2010's36 (21.43)24.3611
2020's17 (10.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.83 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index39.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.68%)5.53%
Reviews4 (2.23%)6.00%
Case Studies1 (0.56%)4.05%
Observational0 (0.00%)0.25%
Other171 (95.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]